Oestrogen receptors and selective oestrogen receptor modulators: Molecular and cellular pharmacology

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 1, 2005, Pages 15-25

  Nilsson, Stefan ^a   Koehler, Konrad F ^a  

^a Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXY 3 PHENYL 4 [4 (2 PIPERIDINOETHOXY)BENZYL] 2H CHROMEN 2 ONE; ACOLBIFENE; BAZEDOXIFENE; CATHEPSIN D; CYCLIN D1; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; GESTAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LASOFOXIFENE; MYC PROTEIN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2; OSPEMIFENE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN P160; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER RISK; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; HUMAN; LIGAND BINDING; NONHUMAN; PLASTICITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; SHORT SURVEY; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANIMALS; CELL PHYSIOLOGY; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 13944279890     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960103.x     Document Type: Short Survey

References (90)

1. Aronica, S. M., W. L. Kraus & B. S. Katzenellenbogen: Estrogen action via cAMP signalling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. USA 1994, 91, 8517-8521.
2. Barkhem, T., B. Carlsson, Y. Nilsson, E. Enmark, J.-Å. Gustafsson & S. Nilsson: Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
3. Beato, M.: Gene regulation by steroid hormones. Cell 1989, 56, 335-344.
4. Benecke, A., P. Chambon & H. Gronemeyer: Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep. 2000, 1, 151-157.
5. Berry, M., D. Metzger & P. Chambon: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9, 2811-2818.
6. Biskobing, D. M., A. M. Novy & R. Downs Jr.: Novel therapeutic options for osteoporosis. Curr. Opin. Rheumatol. 2002, 14, 447-452.
7. Brady, H., M. Doubleday, L. M. Gayo-Fung, M. Hickman, S. Khammungkhune, A. Kois, S. Lipps, S. Pierce, N. Richard, G. Shevlin, M. K. Sutherland, D. W. Anderson, S. S. Bhagwhat & B. Stein: Differential response of estrogen receptors α and β to SP500263, a novel potent selective estrogen receptor modulator. Mol. Pharm. 2002, 3, 562-568.
8. Bramlett, K. S., Y. Wu & T. P. Burris: Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol. Endocrinol. 2001, 15, 909-922.
9. Bruning, P. F., J. M. G. Bonfrer, A. A. M. Hart, M. de Jong-Bakker, D. Linders, J. van Loon & W. J. Nooyen: Tamoxifen, serum lipoproteins and cardiovascular risk. Brit. J. Cancer 1988, 58, 497-499.
10. Chambliss, K. L. & P. W. Shaul: Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae. Steroids 2002, 67, 413-419.
11. Collingwood, T. N., F. D. Urnov & A. P. Wolffe: Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 1999, 23, 255-275.
12. Collins, P. & C. Webb: Estrogen hits the surface. Nature Med. 1999, 5, 1130-1131.
13. Cowley, S. M. & M. G. Parker: A comparison of transcriptional activation by ER alpha and ER beta. J. Steroid. Biochem. Mol. Biol. 1999, 69, 165-175.
14. Delaunay, F., K. Pettersson, M. Tujague & J.-Å. Gustafsson: Functional differences between the amino terminal domains of estrogen receptors α and β. Mol. Pharm. 2000, 58, 584-590.
15. Evans, R. M.: The steroid and thyroid hormone superfamily. Science 1988, 240, 889-895.
16. Galien, R. & T. Garcia: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997, 25, 2424-2429.
17. Gay, F., I. Anglade, Z. Gong & G. Salbert: The LIM/Homeodomain protein Islet-1 modulates estrogen receptor functions. Mol. Endocrinol. 2000, 14, 1627-1648.
18. Giguère, V: Orphan nuclear receptors: from gene to function. Endocrine. Rev. 1999, 20, 689-725.
19. Green, S., P. Walter, V. Kumar, A. Krust, J.-M. Bornert, P. Argos & P. Chambon: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 134-139.
20. Greene, G. L., P. Gilna, M. Waterfield, A. Baker, Y. Hort & J. Shine: Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231, 1150-1154.
21. Hall, J. M. & D. P. McDonnell: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140, 5566-5578.
22. Harrington, W. R., S. Sheng, D. H. Barnett, L. N. Petz, J. A. Katzenellenbogen & B. S. Katzenellenbogen: Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell. Endocrinol. 2003, 206, 13-22.
23. Harris, H. A., L. M. Albert, Y. Leathurby, M. S. Malamas, R. E. Mewshaw, C. P. Miller, Y. P. Kharode, J. Marzolf, B. S. Komm, R. C. Winneker, D. E. Frail, R. A. Henderson, Y. Zhu & J. C. Jr. Keith: Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 2003, 144, 4241-4349.
24. Hodges, L. C., J. D. Cook, E. K. Lobenhofer, L. Li, L. Bennett, P. R. Bushel, C. M. Aldaz, C. A. Afshari & C. L. Walker: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol. Cancer Res. 2003, 1, 300-311.
25. Huang, H. J., J. D. Norris & D. P. McDonnell: Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 2002, 16, 1778-1792.
26. Iannone, M. A., C. A. Simmons, S. H. Kadwell, D. L. Svoboda, D. E. Vanderwall, S. J. Deng, T. G. Consler, J. Shearin, J. G. Gray & K. H. Pearce: Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 2004, 18, 1064-1081.
27. Improta-Brears, T., A. R. Whorton, F. Codazzi, J. D. York, T. Meyer & D. P. McDonnell: Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. USA 1999, 96, 4686-4691.
28. Jordan, V. C.: Tamoxifen: A most unlikely pioneering medicine. Nature Reviews 2003, 2, 205-213.
29. Jordan, V. C., E. Phelps & J. U. Lindgren: Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 1987, 10, 31-35.
30. Katzenellenbogen, B. S. & J. Frasor: Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 2004, 31, 28-38.
31. Kim, K., N. Thu, B. Saville & S. Safe: Domains of estrogen receptor α (ERα) required for ERα/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol. Endocrinol. 2003, 17, 804-817.
32. Kim, S., J. Y. Wu, E. T. Birzin, K. Frisch, W. Chan, L. Y. Pai, Y. T. Yang, R. T. Mosley, P. M. Fitzgerald, N. Sharma, J. Dahllund, A. G. Thorsell, F. DiNinno, S. P. Rohrer, J. M. Schaeffer & M. L. Hammond: Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. J. Med. Chem. 2004, 47, 2171-217.
33. Kraus, W. L. & J. Wong: Nuclear receptor-dependent transcription with chromatin. Is it all about enzymes? Eur. J. Biochem. 2002, 269, 2275-83.
34. Kuiper, G. G. J. M., E. Enmark, M. Pelto-Huikko, S. Nilsson & J.-Å. Gustafsson: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. 1996, 93, 5925-5930.
35. Kushner, P. J., D. A. Agard, G. L. Greene, T. S. Scanlan, A. K. Shiau, R. M. Uht & P. Webb: Estrogen receptor pathways to AP-1. J. Steroid. Biochem. Mol. Biol. 2000, 74, 311-317.
36. Labrie, F., M. El-Alfy, L. Berger, C. Labrie, C. Martel, A. Belanger, B. Candas & G. Pelletier: The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 2003, 144, 4700-4706.
37. Levin, E. R.: Cell localization, physiology, and nongenomic actions of estrogen receptors. J. Appl. Physiol. 2001, 91, 1860-1867.
38. Li, C., M. R. Briggs, T. E. Ahlborn, F. B. Kraemer & J. Liu: Requirement of Sp1 and estrogen receptor α interaction in 17β-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression. Endocrinology 2001, 142, 1546-1553.
39. Love, R. R., H. S. Barden, R. B. Mazess, S. Epstein & R. J. Chappell: Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. 1994a, 154, 2585-2588.
40. Love, R. R., D. A. Wiebe, J. M. Feyzi, P. A. Newcomb & R. J. Chappell: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 1994b, 86, 1534-1539.
41. Maruyama, S., N. Fujimoto, K. Asano & A. Ito: Suppression by estrogen receptor β of AP-1 mediated transactivation through estrogen receptor α. J. Steroid. Biochem. Mol. Biol. 2001, 78, 177-184.
42. McDonnell, D. P. & J. D. Norris: Connections and regulation of the human estrogen receptor. Science 2002, 296, 1642-1644.
43. McDonnell, D. P., D. L. Clemm, T. Hermann, M. E. Goldman & J. W. Pike: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
44. McInerney, E. M., M.-J. Tsai, B. W. O'Malley & B. S. Katzenellenbogen: Analysis of estrogen receptor transcriptional enhancement by a nuclear receptor coactivator. Proc. Natl. Acad. Sci. 1996, 93, 10069-10073.
45. McKennan, N. J. & B. W. O'Malley: Nuclear receptor coactivators - An update. Endocrinology 2002, 143, 2461-2465.
46. Mermelstein, P. G., J. B. Becker & D. J. Surmeier: Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 1996, 16, 595-604.
47. Métivier, R., G. Penot, G. Flouriot & F. Pakdel: Synergism between ERα transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 α-helical core and for a direct interaction between the N- and C-terminal domains. Mol. Endocrinol. 2001, 15, 1953-1970.
48. Métivier, R., A. Stark, G. Fluoriot, M. R. Hübner, H. Brand, G. Penot, D. Manu, S. Denger, G. Reid, M. Kos, R. B. Russell, O. Kah, F. Pakdel & F. Gannon: A dynamic structural model for estrogen receptor-α activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol. Cell 2002, 10, 1019-1032.
49. Migliaccio, A., M. Di Domenico, G. Castoria, A. de Falco, P. Bontempo, E. Nola & F. Auricchio: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. The EMBO J. 1996, 15, 1292-1300.
50. Morello, K. C., G. T. Wurz & M. W. DeGregorio: SERMs: current status and future trends. Crit. Rev. Oncol./Hematol. 2002, 43, 63-76.
51. Morley, P., J. F. Whitfield, B. C. Vanderhyden, B. K. Tsang & J. L. Schwartz: A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 1992, 131, 1305-1312.
52. Nadal, A., J. M. Rovira, O. Laribi, T. Leon-Quinto, E. Andreu, C. Ripoll & B. Soria: Rapid insulinotropic effect of 17beta-estradiol via a plasma membrane receptor. Faseb J. 1998, 12, 1341-1348.
53. Nilsson, S. & J.-Å. Gustafsson: Structure and function of the estrogen receptor. In: Selective estrogen receptor modulators: Research and clinical applications. Eds.: A. Manni & M. F. Verderame. Humana Press Inc, Totowa, NJ, USA, 2002a, pp. 3-18.
54. Nilsson, S. & J.-Å. Gustafsson: Estrogen receptor action. Crit. Rev. Eukaryot. Gene Expr. 2002b, 12, 237-257.
55. Paech, K., P. Webb, G. G. J. M. Kuiper, S. Nilsson, J.-Å. Gustafsson, P. J. Kushner & T. S. Scanlan: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997, 277, 1508-1510.
56. Paige, L. A., D. J. Christensen, H. Grøn, J. D. Norris, E. B. Gottlin, K. M. Padilla, C. Y. Chang, L. M. Ballas, P. T. Hamilton, D. P. McDonnell & D. M. Fowlkes: Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Nat. Acad. Sci. USA 1999, 96, 3999-4004.
57. Pappas, T. C., B. Gametchu & C. S. Watson: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. Faseb J. 1995, 9, 404-410.
58. Pettersson, K., F. Delaunay & J.-A. Gustafsson: Estrogen receptor β acts as a dominant regulator of estrogen signalling. Oncogene 2000, 19, 4970-4978.
59. Pettersson, K., K. Grandien, G. G. J. M. Kuiper & J.-Å. Gustafsson: Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Mol. Endocrinol. 1997, 11, 1486-1496.
60. Pike, A. C. W., A. M. Brzozowski & R. E. Hubbard: A structural biologist's view of the oestrogen receptor. J. Steroid. Biochem. Mol. Biol. 2000, 74, 261-268.
61. Pike, A. C. W, A. M. Brzozowski, J. Walton, R. E. Hubbard, A.-G. Thorsell, Y-L. Li, J.-Å. Gustafsson & M. Carlquist: Structural insights into the mode of action of a pure antiestrogen. Structure 2001, 9, 145-153.
62. Ray, P., S. K. Ghosh, D. H. Zhang & A. Ray: Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 1997, 409, 79-85.
63. Razandi, M., A. Pedram, G. L. Greene & E. R. Levin: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 1999, 13, 307-319.
64. Riggs, B. L. & L. C. Hartmann: Selective estrogen-receptor modulators - Mechanism of action and application to clinical practice. New Engl. J. Med. 2003, 348, 618-629.
65. Safe, S.: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 2001, 62, 231-252.
66. Schaufele, F., C. Y. Chang, W. Liu, J. D. Baxter, S. K. Nordeen, Y. Wan, R. N. Day & D. P. McDonnell: Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. Mol. Endocrinol. 2000, 14, 2024-2039.
67. Shang, Y., X. Hu, J. DiRenzo, M. A. Lazar & M. Brown: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103, 843-852.
68. Shang, Y. & M. Brown: Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468.
69. Simoncini, T. & A. R. Genazzani: Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase.J. Clin. Endocrinol. Metab. 2000, 85, 2966-2969.
70. Simoncini, T., A. R. Genazzani & J. K. Liao: Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002a, 105, 1368-1373.
71. Simoncini, T., G. Varone, L. Fornari, P. Mannella, M. Luisi, F. Labrie & A. R. Genazzani: Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 2002b, 143, 2052-2061.
72. Singer, C. A., X. A. Figueroa-Masot, R. H. Batchelor & D. M. Dorsa: The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J. Neurosci. 1999, 19, 2455-2463.
73. Stein, B. & M. X. Yang: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NFκB and C/EBPβ. Mol. Cell. Biol. 1995, 15, 4971-4979.
74. Sutter-Dub, M.-T.: Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 2002, 67, 77-93.
75. Tee, M. K., I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R. J. Christy, K. R. Yamamoto & D. C. Leitman: Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell 2004, 15, 1262-1272.
76. Teyssier, C., K. Belguise, F. Galtier & D. Chalbos: Characterization of the physical interaction between estrogen receptor α and jun proteins J. Biol. Chem. 2001, 276, 36361-36369.
77. Tremblay, G. B., A. Tremblay, F. Labrie & V. Giguere: Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol. Cell. Biol. 1999a, 19, 1919-1927.
78. Tremblay, A., G. B. Tremblay, F. Labrie & V. Giguère: Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell. 1999b, 3, 513-519.
79. Valentine, J.E., E. Kalkhoven, R. White, S. Hoare & M. G. Parker: Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J. Biol. Chem. 2000, 275, 25322-25329.
80. Viereck, V., C. Gründker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.-H. Frosch, D. Raddatz, G. Emons & L. C. Hofbauer: Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J. Clin. Endocrinol. Metab. 2003, 88, 4206-4213.
81. Watters, J. J., J. S. Campbell, M. J. Cunningham, E. G. Krebs & D. M. Dorsa: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138, 4030-4033.
82. Watters, J. J. & D. M. Dorsa: Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. J. Neurosci. 1998, 18, 6672-6680.
83. Webb, P., P. Nguyen, J. Shinsako, C. Anderson, W. Feng, M. P. Nguyen, D. Chen, S.-M. Huang, S. Subramanian, E. McKinerney, B. S. Katzenellenbogen, M. R. Stallcup & P. J. Kushner: Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 1998, 12, 1605-1618.
84. Webb, P., P. Nguyen & P. J. Kushner: Differential SERM effects on corepressor binding dictate ERα activity in vivo. J. Biol. Chem. 2003, 278, 6912-6920.
85. Wijayaratne, A. L., S. C. Nagel, L. A. Paige, D. J. Christensen, J. D. Norris, D. M. Fowlkes & D. P. McDonnell: Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999, 140, 5828-5840.
86. Wong, C.-W., B. Komm & B. J. Cheskis: Structure-function evaluation of ERα and β interplay with SRC family coactivators. ER selective ligands. Biochemistry 2001, 40, 6756-6765.
87. Writing Group for the Women's Health Initiative Investigators: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the women's health initiative randomized controlled trial. JAMA 2002, 288, 321-333.
88. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004, 291, 1701-1712.
89. Yang, C., R. Jr. Edsall, H. A. Harris, X. Zhang, E. S. Manas & R. E. Mewshaw: ERbeta Ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg. Med. Chem. 2004, 12, 2553-2570.
90. Zhou, Y., J. J. Watters & D. M. Dorsa: Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 1996, 137, 2163-2166.